Canaccord analyst John Young raised the firm’s price target on Merit Medical (MMSI) to $104 from $103 and keeps a Buy rating on the shares. The firm updated its model following the announcement of a proposed acquisition from PENTAX Medical pf its C2 CryoBalloon Ablation System; a focal ablation system that expands Merit’s Endoscopy product portfolio and will complement its acquisition of Endogastric Solutions that it made last year.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical to acquire C2 CryoBalloon device for $22M, sees dilution
- Merit Medical Systems Announces New CEO Appointment
- Merit Medical says SCOUT Radar Localization use reaches 750,000 patients
- Merit Medical Systems: Promising Growth Potential Driven by Innovation, Strategic Acquisitions, and Strong Financials
- Merit Medical announces first patient enrolled WRAP North America registry